Veliparib is a drug with a complex mechanism of action that makes it useful for the treatment of various types of cancer. Its chemical name is 1,3-diethyl-8-methyl-2,6-dioxo-2,3,4,6,8,9- hexahydro-1H- pyrrolo[3,2,1-ij]quinoline-5-carboxamide, and its molecular formula is C13H16N4O3. The formula weight of veliparib is 268.3 g/mol, and its CAS No. is 912444-00-9.
Keywords:
Synonyms:
Health Benefits of Veliparib Veliparib is an effective PARP inhibitor for treating various types of cancer. It works by blocking the activity of poly (ADP-ribose) polymerase (PARP), an enzyme that assists in DNA repair. By blocking this enzyme, Veliparib can reduce the efficacy of the DNA damage repair process and the viability of cancer cells.
Potential Effects of Veliparib Veliparib has been shown to be effective in treating cancer, particularly ovarian and breast cancers. It is often used in a combination of chemotherapy treatments to boost the efficacy of chemotherapy drugs. Inhibiting PARP activity can cause synthetic lethality in cancer cells with BRCA1/2 mutations that fail to complete efficient homologous recombination, one the DNA repair pathways commonly used by normal cells and especially tumour cells.
Product Mechanism Veliparib works by inhibiting PARP activity, which helps to reduce the efficacy of the DNA damage repair process, therefore cto cause fatal errors during these repair attempts that ultimately lead to cell death. This is particularly effective in cancer cells that have lost their ability to rely on other DNA repair mechanisms, such as BRCA1/2 mutations. Consequently, it impedes cancer cell growth and causes cell death.
Safety of Veliparib Clinical trials have shown veliparib is a generally safe drug. Like most other drugs under clinical stages, there is a possibility of adverse effects when taken for extended periods. However, the side effects of veliparib are mild and manageable, and the drug is generally well-tolerated by patients.
Side Effects Veliparib's side effects are mild and manageable, similar to other chemotherapy drugs. The most common side effects observed during trials included fatigue, loss of appetite, nausea, vomiting and headache. Other adverse effects included diarrhea, constipation, anemia, and elevated hepatic enzymes.
Dosing Information The dosing information for Veliparib varies depending on the type and stage of the cancer being treated. Typically, it is taken twice daily orally, and the dosage is determined based on individual patient tolerance and response.
Conclusion Veliparib is a promising new drug for treating various types of cancer, especially ovarian and breast cancer. Its unique mechanism of action makes it effective in reducing the efficacy of the DNA damage repair process, resulting in cancer cell apoptosis. Additionally, Veliparib is generally safe and well-tolerated by patients, with only mild and manageable side effects. Veliparib is currently being used in clinical trials, and its successful implementation may lead to the development of new and safer chemotherapy drugs.
